Toshifumi Hoki

Merck & Co., Inc., Rahway, NJ, USA (United States)

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors”.

A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.06.13.095844

N/A

0DataRank · unranked

3 citations

Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood +11 more

CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1 + CD8 + T cells in mice

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.06.15.151787

N/A

0DataRank · unranked

2 citations

Toshifumi Hoki, Takaaki Oba, Kristopher Attwood, Xuefang Cao, Fumito Ito +1 more

T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors

Nature Communications(2021)10.1038/s41467-021-21619-0

N/A

0DataRank · unranked

188 citations

Toshifumi Hoki, Takaaki Oba, Vaibhav Jain, Hongbin Chen, Kristopher Attwood +11 more

CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1+ CD8+ T cells

Cancer Immunology Immunotherapy(2021)10.1007/s00262-021-02969-6

N/A

0DataRank · unranked

28 citations

Toshifumi Hoki, Takaaki Oba, Ryutaro Kajihara, Kristopher Attwood, Xuefang Cao +2 more